Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy
Pepin A, Shah S, Pernia M, Lei S, Ayoob M, Danner M, Yung T, Collins BT, Suy S, Aghdam N, Collins SP | Front Oncol | 2021
Five-year outcomes of stereotactic body radiation therapy (SBRT) for prostate cancer: the largest experience in China
Zhao X, Ye Y, Yu H, Jiang L, Cheng C, Guo X, Ju X, Zhu X, Zhang H. | J Cancer Res Clin Oncol | 2021
Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer
Sarthak Shah, Tamir Sholklapper , Michael Creswell, Abigail Pepin , Jonathan Cantalino, Ryan Andrew Hankins, Simeng Suy, Sean P Collins | Front Oncol | 2021
Short-Term Outcomes and Clinical Efficacy of Stereotactic Body Radiation Therapy (SBRT) for Oligometastases of Prostate Cancer in China
Chenyang Xu, Xianzhi Zhao, Xiaoping Ju, Yuxin Shen, Min Qu, Yusheng Ye, Xiaoyan Wang, Chunshan Yu, Xu Gao, Huojun Zhang | Front Oncol | 2022
High Dose “HDR-Like” Prostate SBRT: PSA 10-Year Results From a Mature, Multi-Institutional Clinical Trial
Fuller DB, Crabtree T, Kane BL, Medbery CA, Pfeffer R, Gray JR, Peddada A, Royce TJ, Chen RC | Front Oncol | 2022
